Insights
Estimating the Impact of U.S. Drug Price-setting Policies on Innovation Is Challenging, Even for the Congressional Budget Office
22 June 2022
Since the Office of Health Economics (OHE) published a critique of CBO’s new simulation model of new drug development late last year, the U.S. public sector think tank has made three improvements to its methodology. We review these updates, assess their impact, and highlight the key remaining limitations of the modelling approach, concluding that policymakers should still exercise considerable caution in relying on its predictions.
ISPOR Issue Panel Roundup: Are Our HTA Methods Fit for Purpose for Gene Therapies?
6 June 2022
As part of OHE’s presence at ISPOR 2022 in Washington DC, we hosted an issue panel tackling the hot topic of health technology assessment (HTA) of…
Sleepio: Lessons from the Frontier of Digital Therapeutics
31 May 2022
The National Institute for Health and Care Excellence (NICE) recently issued its first guidance for a digital therapeutic. NICE recommends the use of Sleepio for treating…
Open Source Modelling: From Ideas to Action
16 May 2022
OHE’s Chris Sampson is currently Chair of the ISPOR Open Source Models Special Interest Group (SIG). The SIG recently published their first journal article in Value…
Ignoring the needs of our future workforce could have disastrous consequences for the UK NHS and its patients.
12 May 2022
Ignoring the needs of our future workforce could have disastrous consequences for the UK NHS and its patients. In economics, we have a pretty complicated name…
Accounting for Preference Heterogeneity in Discrete Choice Experiments
4 May 2022
A new publication co-authored by OHE’s David Mott provides an overview of the state of practice for accounting for preference heterogeneity in discrete choice experiments. The…
Let’s talk about (health) inequalities
1 April 2022
The NICE methods review consultation included a proposal to consider health inequalities more explicitly in their Health Technology Assessment process. But there is still a long…
Invest to End TB. Save Lives. World TB Day 2022. Reflections on 60 years of OHE publications on TB
24 March 2022
Global TB deaths are increasing. CGD and OHE set out a “Market-Driven, Value-Based, Advance Commitment (MVAC)” that would create and guarantee a market for a breakthrough…
NICE’s severity modifier: a step in the right direction, but still a long way to go
23 March 2022
This blog post is the fifth in a series on the new National Institute for Health and Care Excellence (NICE) health technology evaluation manual. Each post…